Business
Scancell and CRUK provide an update on SCIB2
Scancell and CRUK provide an update on SCIB2.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 4804Z Scancell Holdings Plc 20 May 2019 \n\n20 May 2019\n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \nScancell and Cancer Research UK provide an update on the development of SCIB2, a novel cancer immunotherapy \n \n SCIB2 to be administered using new nanoparticle formulation in planned Phase 1/2 clinical trial\n \nScancell Holdings PLC, a developer of novel immunotherapies for the treatment of cancer, and Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research, are pleased to provide an update on their clinical development partnership* for the development of Scancell's ImmunoBody® vaccine, SCIB2, as a potential treatment for patients with solid tumours, including non-small cell lung cancer (NSCLC). \n \nScancell's ImmunoBody® immunotherapy platform activates the body's immune system by enhancing the uptake and presentation of cancer antigens to help target and eliminate cancer cells. SCIB2, Scancell's second ImmunoBody® therapy, targets an antigen called NY-ESO-1, which is expressed on a range of solid tumours, including NSCLC, oesophageal, ovarian, bladder and prostate cancers, neuroblastoma, melanoma and sarcoma. \n \nPre-clinical studies have demonstrated that administration of SCIB2 as a liposomal nanoparticle results in potent immune responses and prolonged survival. The nanoparticle technology utilises known lipid carriers that are optimised to deliver SCIB2 DNA to immune cells. The liposomal nanoparticles protect the DNA from degradation and facilitate efficient uptake, expression and T-cell activation against cancer cells. The nanoparticle delivery system provides an alternative approach to electroporation, which has been used to deliver other ImmunoBody® agents to patients. Cancer Research UK are now planning a clinical trial to investigate the safety and efficacy of the SCIB2-nanoparticle complex in patients with solid tumours. \n \nDr Cliff Holloway, Chief Executive Officer of Scancell, commented: \n \n\"We are delighted to announce this important milestone in our partnership with Cancer Research UK, which moves us one step closer to entering the clinic. This new nanoparticle approach to deliver SCIB2 is expected to achieve results that are as effective as, or even better than, electroporat...